Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karen Levy

Optometrist Collingswood, NJ Doctor of Optometry

NPI 1538699582 CMS profile 3701674

900 Haddon Ave Ste 102, Collingswood, NJ 08108

Open in the dashboard

General payments

$2,906

147 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Levy of Collingswood, NJ is reported in the CMS Open Payments database as having received $2,906 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $481 30
2024 General $787 35
2023 General $716 31
2022 General $335 18
2021 General $154 10
2020 General $134 8
2019 General $299 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Levy
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Karen Levy were reported at $481. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Karen Levy Optometrist median Middle half National median
2019 $299 $159 $67–$371 $163
2020 $134 $72 $29–$165 $114
2021 $154 $125 $46–$292 $132
2022 $335 $162 $66–$374 $149
2023 $716 $177 $72–$406 $160
2024 $787 $188 $77–$427 $164
2025 $481 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $776 51 payments
  2. Alcon Vision LLC $414 17 payments
  3. Sun Pharmaceutical Industries Inc. $218 14 payments
  4. Oyster Point Pharma, Inc. $191 11 payments
  5. Genzyme Corporation $187 2 payments
  6. Horizon Therapeutics plc $141 2 payments
  7. Bausch & Lomb, a division of Bausch Health US, LLC $122 9 payments
  8. Amgen Inc. $104 2 payments
  9. MacuLogix, Inc. $97 1 payment
  10. Novartis Pharmaceuticals Corporation $97 7 payments
  11. Other $560 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,890 146 payments
  2. Entertainment $16 1 payment
Products named General payments · program years 2019–2025
  1. INFUSE $576 28 payments
  2. Cequa $180 11 payments
  3. XIIDRA $156 17 payments
  4. TEPEZZA Tepezza $141 2 payments
  5. ARGOS $135 1 payment
  6. VYZULTA $118 9 payments
  7. FABRAZYME $107 1 payment
  8. TEPEZZA Inflammation/Rare Disease $104 2 payments
  9. TYRVAYA $98 5 payments
  10. TOTAL30 $97 6 payments
  11. Other $1,527 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

216

Median for Optometry: 120

Drug cost

$29,370

Median for Optometry: $8,864

Branded share of claims

51.9%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xiidra Lifitegrast Brand 16 $23,714
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 65 $2,153
Loteprednol Etabonate Generic 15 $1,646
Prednisolone Acetate Generic 27 $1,031
Doxycycline Hyclate Generic 11 $274
Latanoprost Generic 51 $198
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 16 $185
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 15 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$52,487

Medicare's payments for the services billed

Medicare patients

369

Average age 72

Services billed

864

222 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 45%
Diabetes 25%
Ischemic heart disease 21%
Chronic kidney disease 17%
COPD 16%
Atrial fibrillation 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FABRAZYME
  • GENZYME CORPORATION $107
$107 — —
TEPEZZA
  • Amgen Inc. $104
$104 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $74
$74 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $59
$59 16 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record